New Frontiers in MASH and Chronic Liver Diseases with Aligos CEO Dr. Lawrence Blatt

Xtalks Life Science Podcast

In this episode, Ayesha spoke with Lawrence Blatt, PhD, MBA, Chairman and CEO of Aligos Therapeutics, a company developing targeted therapies for liver diseases like MASH (metabolic dysfunction-associated steatohepatitis) and viral diseases to address important unmet medical needs.

Prior to co-founding Aligos Therapeutics, Dr. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson from 2014 to 2018. He also co-founded several biotech companies, including Alios BioPharma, which was acquired by Janssen in November 2014. Dr. Blatt previously served on the board of directors of companies including ReViral Ltd. and Alveo Technologies, Inc., which he co-founded in 2014, and Meissa Vaccines, Inc. Dr. Blatt received an MBA from California State University, Northridge, and a PhD in Public Health Administration from the University of La Verne.

In March, Aligos announced the dosing of its first patient in its Phase IIa trial for a novel thyroid hormone receptor-beta agonist (ALG-055009) designed to address the root fibrosis of MASH. The drug is in the same class as Rezdiffra, which was approved this year as the first treatment for MASH.

Aligos also shared positive data at the European Association for the Study of the Liver (EASL) Congress last month in Milan, Italy for one of its candidate therapeutics for chronic hepatitis B (CHB).

Tune into the episode to learn more about the work Dr. Blatt is leading at Aligos Therapeutics in chronic liver disease and viral diseases.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured